BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square - 2'People We Meet on Vacation' is the 1st of many Emily Henry adaptations: What other books turned movies to look forward to
- 3Getting Your Youngsters' Future: Grasping Legacy Regulations
- 4Changing Negative Cash Mentalities: Enabling Your Monetary Excursion
- 5The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- Dental, Vision, and Hearing Inclusion in Senior Protection.
- Unwinding the Starting points of America: An Excursion Through History
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- Washington resident contracts bird flu, first human case in U.S. since February
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- Some Americans say they'll go without health insurance as ACA rates spike
- The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Bolsonaro briefly leaves Brazilian prison for medical tests after a fall from his bed
- Kissing is an ‘evolutionary conundrum.’ Scientists just mapped its unexpected origins
